GSK’s Exdensur receives Japan’s MHLW approval for severe asthma and chronic rhinosinusitis with nasal polyps: London, UK Wednesday, January 7, 2026, 10:00 Hrs [IST] GSK plc an ...
Another common reason for nosebleeds is “digital manipulation, which is a nice way of saying nose picking or scratching your ...
GSK has secured approval in Japan for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps. Approved by Japan’s ...
GSK said Japan's Ministry of Health had approved its bronchial asthma treatment Exdensur after trial results showed ...
(Alliance News) - GSK PLC on Tuesday said depemokimab, sold under the brand name Exdensur, has been approved by Japan's Ministry of Health, Labour and Welfare for severe asthma and chronic ...
GSK on Tuesday said Japan’s Ministry of Health, Labour and Welfare approved Exdensur, also known as depemokimab, for patients ...
What Changed in the Amgen Story Amgen’s fair value estimate has been adjusted slightly, moving from about US$322.88 per share ...
A Canadian real-world study reveals high oral corticosteroid exposure in patients with severe chronic rhinosinusitis with ...
Dr Philippa Kaye answers: A constantly runny or blocked nose would usually be due to a condition called rhinitis – ...
I am a 76-year-old male who is in relatively good health. For the past six months, I have been experiencing diarrhea on and ...
GSK plc (NYSE:GSK) is included among the 15 Global Dividend Stocks to Diversify Your Portfolio. On December 10, HSBC analyst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback